Study Demonstrates Potential for the Guardant360 Assay® to Predict Which Patients Will Benefit from Immunotherapy – Markets Insider
|
Study Demonstrates Potential for the Guardant360 Assay® to Predict Which Patients Will Benefit from Immunotherapy
Markets Insider REDWOOD CITY, Calif., Oct. 2, 2017 /PRNewswire/ — Oncologists may get a new tool for identifying which of their cancer patients are most likely to respond to widely prescribed immunotherapies, recent research suggests. In a paper published in Clinical … |
